etrumadenant + zimberelimab + enzalutamide

A combination regimen of etrumadenant, zimberelimab, and enzalutamide combines the activities of three distinct agents: **etrumadenant**, a small molecule dual antagonist of the adenosine A2a and A2b receptors which aims to reverse adenosine-mediated immunosuppression in the tumor microenvironment; **zimberelimab**, an anti-PD-1 monoclonal antibody immunotherapy targeting programmed cell death 1 (PD-1); and **enzalutamide**, an oral androgen receptor inhibitor that blocks androgen-induced tumor cell proliferation. This combination is being evaluated in oncology, notably in metastatic colorectal cancer and solid tumors, for its potential to synergistically enhance antitumor immune responses and provide benefit where standard therapies have failed[1][2][4][3].